Name
of applicant:
|
GSK
plc
|
|||
Name of
scheme:
|
GlaxoSmithKline
plc 2017 Deferred Annual Bonus Plan
|
|||
Period
of return:
|
From:
|
1
November 2024
|
To:
|
30
April 2025
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
115,518
|
|||
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|||
Less: Number
of securities issued/allotted under
scheme(s) during period (see UKLR 20.6.7G):
|
0
|
|||
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
115,518
|
Name
of applicant:
|
GSK
plc
|
|||
Name of
scheme:
|
GlaxoSmithKline
plc Share Save Plan 2012
|
|||
Period
of return:
|
From:
|
1
November 2024
|
To:
|
30
April 2025
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
517,238
|
|||
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
700,000
|
|||
Less: Number
of securities issued/allotted under
scheme(s) during period (see UKLR 20.6.7G):
|
946,923
|
|||
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
270,315
|
Name
of applicant:
|
GSK
plc
|
|||
Name of
scheme:
|
GlaxoSmithKline
plc Share Save Plan 2022
|
|||
Period
of return:
|
From:
|
1
November 2024
|
To:
|
30
April 2025
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
975,390
|
|||
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|||
Less: Number
of securities issued/allotted under
scheme(s) during period (see UKLR 20.6.7G):
|
23,599
|
|||
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
951,791
|
Name of
contact:
|
Victoria
Whyte
|
Telephone
number of contact:
|
020
8047 5000
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: May
12, 2025
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|